| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.09B | +40.3% |
| Gross profit | ¥0.05B | — |
| Operating income | ¥-0.77B | — |
| Net income | ¥-0.77B | — |
| Gross margin | 54.1% | Net margin -818.9% |
| Revenue Q/Q | -79.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 化药制剂 | ¥0.07B | 78.5% |
| 中成药制剂 | ¥0.02B | 18.8% |
| 其他主营业务 | ¥0.00B | 2.8% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.04B | 45.9% |
| R&D | ¥0.69B | 734.5% |
| SG&A | ¥0.13B | 133.6% |
| Tax & other | ¥0.00B | 0.3% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
芯原股份 ・ 中芯国际 ・ 特锐德 ・ 神州泰岳 ・ 乐普医疗 ・ 南风股份 ・ 探路者 ・ 莱美药业 ・ 汉威科技 ・ 天海防务 ・ 安科生物 ・ ST豆神
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies